Status:
UNKNOWN
Line Versus Spot Ablation in Persistent Atrial Fibrillation
Lead Sponsor:
Deutsches Herzzentrum Muenchen
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
In this randomized study dealing with the ablative treatment of persistent atrial fibrillation, two ablation strategies are compared: a more anatomically guided linear ablation scheme versus an electr...
Detailed Description
This randomized study deals with two different ablative treatment strategies for persistent atrial fibrillation: a more anatomically guided linear ablation scheme with encircling of the ipsilateral pu...
Eligibility Criteria
Inclusion
- age between 18 and 80 years
- symptomatic persistent (\> 7 days lasting) atrial fibrillation
- at least one unsuccessful cardioversion or atrial fibrillation relapse in the first 3 months after cardioversion despite antiarrhythmic drug therapy
- oral anticoagulation (\> 4 weeks prior to ablation)
Exclusion
- moderate to severe valvular heart disease
- congenital heart disease
- LV-EF \< 35%
- reversible cause for atrial fibrillation (e.g., hyperthyreosis)
- prior left atrial ablation or Maze operation
- left atrial thrombus
Key Trial Info
Start Date :
August 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2008
Estimated Enrollment :
116 Patients enrolled
Trial Details
Trial ID
NCT00196157
Start Date
August 1 2004
End Date
November 1 2008
Last Update
May 29 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Deutsches Herzzentrum Muenchen
Munich, Germany, 80636